We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The selected candidates (hits) with anti-coronavirus activity will be subjected to study of their molecular mechanism of action, besides examining generation of potential drug-resistant virus variants.
Merck has signed an exclusive worldwide research collaboration and licence agreement with two Otsuka Pharmaceutical subsidiaries, Japanese Taiho Pharmaceutical and UK-based Astex Pharmaceuticals.